Versant Capital Management
SLDB icon

Versant Capital Management’s Solid Biosciences SLDB Stock Holding History

Versant Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$774 Hold
107
– – ﹤0.01% 2733
2026
Q2 		$1.07K Buy
+107
New +$811 ﹤0.01% 2637

Other funds holding SLDB

Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Quantum Private Wealth
Quantum Private Wealth Tampa, Florida $391M AUM 50.76% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
Physician Wealth Advisors
Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Versant Capital Management's SLDB Position: Q3 2026 in Review

Versant Capital Management held its Solid Biosciences (SLDB) position steady in Q3 2026 at 107 shares worth $774. The position accounts for ﹤0.01% of the portfolio, ranked #2733.

Versant Capital Management first reported a position in SLDB in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.07K in Q2 2026. 13 funds tracked by Wall St. Rank hold SLDB as of Q3 2026.

  • Versant Capital Management held 107 shares of Solid Biosciences worth $774 as of Q3 2026.
  • Versant Capital Management left its Solid Biosciences share count unchanged in Q3 2026.
  • Solid Biosciences made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2733 holding.
  • Versant Capital Management first reported a position in Solid Biosciences in Q2 2026 and has held it in 2 quarters since.
  • Versant Capital Management's Solid Biosciences position peaked at $1.07K in Q2 2026.
  • 13 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.